GSA Capital Partners’s Theravance Biopharma TBPH Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-58,379	Closed	-$1.09M	–	2147
2025 Q4	$1.09M	Sell	58,379 -33,802	-37%	-$561K	0.09%	315
2025 Q3	$1.35M	Sell	92,181 -45,770	-33%	-$578K	0.11%	233
2025 Q2	$1.52M	Sell	137,951 -44,399	-24%	-$432K	0.11%	230
2025 Q1	$1.63M	Buy	182,350 +19,363	+12%	+$180K	0.15%	136
2024 Q4	$1.53M	Sell	162,987 -66,793	-29%	-$608K	0.11%	183
2024 Q3	$1.85M	Buy	229,780 +25,691	+13%	+$223K	0.14%	151
2024 Q2	$1.73M	Buy	+204,089	New	+$1.84M	0.12%	207
2024 Q1	–	Sell	-77,070	Closed	-$866K	–	1959
2023 Q4	$866K	Sell	77,070 -248,915	-76%	-$2.51M	0.07%	464
2023 Q3	$2.81M	Buy	325,985 +306,064	+1,536%	+$2.95M	0.24%	41
2023 Q2	$206K	Sell	19,921 -85,342	-81%	-$942K	0.02%	1253
2023 Q1	$1.14M	Buy	105,263 +47,686	+83%	+$504K	0.11%	252
2022 Q4	$646K	Buy	+57,577	New	+$605K	0.08%	440
2022 Q3	–	Sell	-114,646	Closed	-$1.04M	–	1850
2022 Q2	$1.04M	Buy	114,646 +65,190	+132%	+$601K	0.16%	133
2022 Q1	$473K	Buy	+49,456	New	+$485K	0.06%	569
2020 Q4	–	Sell	-13,965	Closed	-$206K	–	1584
2020 Q3	$206K	Buy	+13,965	New	+$262K	0.03%	992
2019 Q4	–	Sell	-10,745	Closed	-$209K	–	1720
2019 Q3	$209K	Buy	+10,745	New	+$217K	0.03%	1153